HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) All Versions of this Article: jnnp.2006.090365v1 77/8/918    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kobelt, G Articles by Jönsson, B Search for Related Content PubMed PubMed Citation Articles by Kobelt, G Articles by Jönsson, B

Costs and quality of life of patients with multiple sclerosis in Europe

¹ Lund University, Lund, Sweden
² Stockholm Health Economics, Stockholm
³ Department of Neurology, Karolinska Institute, Huddinge Hospital, Stockholm
⁴ Stockholm School of Economics, Stockholm

Correspondence to:
Correspondence to:
G Kobelt
European Health Economics, 492 Chemin des Laurens, F-06530 Speracedes, France; gisela.kobelt{at}he-europe.com

Objective: To assess overall resource consumption, work capacity and quality of life of patients with multiple sclerosis in nine European countries.

Methods: Information on resource consumption related to multiple sclerosis, informal care by relatives, productivity losses and overall quality of life (utility) was collected with a standardised pre-tested questionnaire from 13 186 patients enrolled in national multiple sclerosis societies or followed up in neurology clinics. Information on disease included disease duration, self-assessed disease severity and relapses. Mean annual costs per patient (, 2005) were estimated from the societal perspective.

Results: The mean age ranged from 45.1 to 53.4 years, and all levels of disease severity were represented. Between 16% and 29% of patients reported experiencing a relapse in the 3 months preceding data collection. The proportion of patients in early retirement because of multiple sclerosis ranged from 33% to 45%. The use of direct medical resources (eg, hospitalisation, consultations and drugs) varied considerably across countries, whereas the use of non-medical resources (eg, walking sticks, wheel chairs, modifications to house and car) and services (eg, home care and transportation) was comparable. Informal care use was highly correlated with disease severity, but was further influenced by healthcare systems and family structure. All types of costs increased with worsening disease. The total mean annual costs per patient (adjusted for gross domestic product purchasing power) were estimated at 18 000 for mild disease (Expanded Disability Status Scale (EDSS) <4.0), 36 500 for moderate disease (EDSS 4.0–6.5) and 62 000 for severe disease (EDSS >7.0). Utility was similar across countries at around 0.70 for a patient with an EDSS of 2.0 and around 0.45 for a patient with an EDSS of 6.5. Intangible costs were estimated at around 13 000 per patient.

Abbreviations: DMD, disease-modifying drugs; EDSS, Expanded Disability Status Scale; EQ-5D, EuroQol; GDP, gross domestic product; QALY, quality-adjusted life year; QoL, quality of life

This article has been cited by other articles:

				K Gottberg, U Einarsson, C Ytterberg, S Fredrikson, L von Koch, and L W. Holmqvist Use of health care services and satisfaction with care in people with multiple sclerosis in Stockholm County: A population-based study Multiple Sclerosis, August 1, 2008; 14(7): 962 - 971. [Abstract] [PDF]

				G Kobelt, J Berg, P Lindgren, B Jonsson, L Stawiarz, and J Hillert Modeling the cost-effectiveness of a new treatment for MS (natalizumab) compared with current standard practice in Sweden Multiple Sclerosis, June 1, 2008; 14(5): 679 - 690. [Abstract] [PDF]

				A. Ringborg, R. Nieuwlaat, P. Lindgren, B. Jonsson, D. Fidan, A. P. Maggioni, J. Lopez-Sendon, J. Stepinska, D. V. Cokkinos, and H. J.G.M. Crijns Costs of atrial fibrillation in five European countries: results from the Euro Heart Survey on atrial fibrillation Europace, April 1, 2008; 10(4): 403 - 411. [Abstract] [Full Text] [PDF]

				F. Marrosu, A. Maleci, E. Cocco, M. Puligheddu, L. Barberini, and M.G. Marrosu Vagal nerve stimulation improves cerebellar tremor and dysphagia in multiple sclerosis Multiple Sclerosis, November 1, 2007; 13(9): 1200 - 1202. [Abstract] [PDF]

				R. M. Ransohoff Natalizumab for Multiple Sclerosis N. Engl. J. Med., June 21, 2007; 356(25): 2622 - 2629. [Full Text] [PDF]